Free tool
Oncology stocks
We cover 12 companies grouped under the Oncology theme. The median market value in the group is $325.92M. Across the group, the median move over the past trading day is +0.74%. Price change over the past year runs from −21.5% to +391.3% across the middle 80 percent of the group, with a median of +12.5%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
12 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | $14.23 | +13.39% | −18.78% | −42.63% | Oct 19, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $26.71 | +10.60% | +47.90% | +179.69% | Oct 8, 2026 |
| NBTX | Nanobiotix S.A. | $44.50 | +17.66% | +101.08% | +394.99% | Sep 29, 2026 |
| NANO.PA | Nanobiotix S.A. | 35.74 EUR | +8.43% | +88.11% | +358.21% | Sep 29, 2026 |
| 0QAV.L | Nanobiotix S.A. | 35.02 EUR | −1.38% | +82.87% | +351.98% | Sep 29, 2026 |
| PRTC.L | PureTech Health plc | 121.20 GBP | +0.17% | −2.73% | −4.27% | Aug 27, 2026 |
| IPHA | Innate Pharma S.A. | $2.16 | +28.57% | +18.68% | +2.86% | Sep 17, 2026 |
| IDD.DE | Innate Pharma S.A. | 1.78 EUR | +12.80% | +12.80% | −2.52% | Sep 17, 2026 |
| IPH.PA | Innate Pharma S.A. | 1.88 EUR | +19.01% | +16.21% | +1.19% | Sep 17, 2026 |
| BINV.ST | BioInvent International AB (publ) | 24.30 SEK | +5.42% | −17.21% | −23.46% | Aug 27, 2026 |
| 0RU5.L | Oncoinvent ASA | 85.40 NOK | 0.00% | +96.77% | +7339.02% | Aug 27, 2026 |
| ANIX | Anixa Biosciences, Inc. | $3.61 | +2.41% | +14.08% | +22.20% | Sep 9, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.